Human medicines European public assessment report (EPAR): Bavencio, avelumab, Neuroendocrine Tumors, Date of authorisation: 18/09/2017, Revision: 16, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Gold (Au), decision type: , therapeutic area: , PIP number: P/0301/2022

Opinion/decision on a Paediatric investigation plan (PIP): Doxecitine,Doxribtimine, decision type: , therapeutic area: , PIP number: P/0287/2022

Opinion/decision on a Paediatric investigation plan (PIP): Acetylsalicylic acid,rosuvastatin calcium, decision type: , therapeutic area: , PIP number: P/0281/2022

Opinion/decision on a Paediatric investigation plan (PIP): atorvastatin,Ezetimibe, decision type: , therapeutic area: , PIP number: P/0272/2022

Opinion/decision on a Paediatric investigation plan (PIP): fidanacogene elaparvovec, decision type: , therapeutic area: , PIP number: P/0277/2022

Human medicines European public assessment report (EPAR): Cosentyx, secukinumab, Arthritis, Psoriatic;Psoriasis;Spondylitis, Ankylosing, Date of authorisation: 14/01/2015, Revision: 34, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Deucravacitinib, decision type: , therapeutic area: , PIP number: P/0278/2022

ACT EU PA04 - Multi-stakeholder Workshop on ICH E6 R3 - Public Consultation, Online and European Medicines Agency, Amsterdam, the Netherlands, from 13/07/2023 to 14/07/2023

Opinion/decision on a Paediatric investigation plan (PIP): Rezafungin acetate, decision type: , therapeutic area: , PIP number: P/0342/2022